Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1001316 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $53.48Day −2.53%Mkt cap $8.2BP/E (FY) 19.3×1Y +51.4%Off 52W high −9.8%Vol (1Y) 49.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,773 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 75.9% growth |
| Short interest20.0% of sh out |
| Days to cover15.4d |
| 13F net flow (QoQ)+1.79% |
| Top-10 13F concentration59.8% |
| Next report (est.)2026-08-05 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)19.3× |
| Sales (TTM)$700.3M |
| Earnings (TTM)$461.9M |
| ROE102.8% |
| Net margin72.6% |
| ROIC27.2% |
| YTD+79.4% |
| 1Y+51.4% |
| 3Y+158.5% |
| 5Y+49.9% |
| 10Y+804.9% |
| Since incept. (ann.)+76.9% |
Total return through 2026-07-29 · series begins 2011-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)49.6% |
| Ann. volatility (3Y)68.7% |
| Sharpe (1Y)1.05 |
| Sharpe (3Y)0.85 |
| Max drawdown (1Y)−27.2% |
| Max drawdown (3Y)−67.7% |
| Beta (3Y vs SPY)1.74 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 22.3M | $739M | 13.94% | +1.9% |
| STATE STREET CORP | 8.6M | $287M | 5.42% | +2.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.3M | $275M | 5.18% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.6M | $219M | 4.14% | new |
| Soleus Capital Management, L.P. | 4.0M | $134M | 2.52% | +28.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $116M | 2.19% | +2.8% |
| Clearbridge Investments, LLC | 3.2M | $107M | 2.01% | −6.9% |
| GOLDMAN SACHS GROUP INC | 2.3M | $76M | 1.43% | +11.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.12 | +300.0% | $204.9M | +69.6% |
| 2025-12-31 | 2026-02-26 | — | — | $192.6M | +78.0% |
| 2025-09-30 | 2025-11-03 | $2.43 | +12050.0% | $161.7M | +92.8% |
| 2025-06-30 | 2025-08-04 | $0.17 | +325.0% | $141.1M | +92.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 97% · License 1% · Royalty 1% · Other Revenue 1% · License Revenue 0%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Debt / equity0.38× |
| Total debt / EBITDA1.99× |
| Sales growth 3Y504.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
